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Abstract. The aim of this study was to evaluate the effectiveness of benznidazole nanoparticles (BNZ-nps) on
trypomastigote forms and on intracellular infection in mammalian cells and primary cardiac myocyte cells. Its effective-
ness was also evaluated on acute Trypanosoma cruzi Nicaragua mice infection. Trypomastigotes from culture were
treated with different concentrations of BNZ-nps to determine the drug concentration that lyses 50% of trypomastigotes
(LC50). Infected mammalian cells were incubated with different concentrations of BNZ-nps to determine the percentage
of amastigote inhibition. C3H/HeN mice with lethal acute infection were treated with 10, 25, and 50 mg/kg/day of BNZ-
nps for 30 and 15 days to control the survival rate of animals. BNZ-nps having a mean particle size of 63.3 nm, a size
distribution of 3.35, and a zeta potential of −18.30 were successfully prepared using poloxamer 188 as a stabilizer.
BNZ-nps 25 and 50 μg/mL showed no significant differences in the percentage of inhibition of infected mammalian
cells. Infected mice treated with BNZ-nps (50, 25, and 10 mg/kg/day) for 30 days and with BNZ-nps (50 and 25 mg/kg/day)
for 15 days presented a 100% survival, whereas the animals treated with 10 mg/kg/day for 15 days of BNZ-nps showed
a 70% survival rate. The results obtained demonstrate, for the first time, that benznidazole nanoparticles are a useful
and attractive approach to treat Chagas disease in infected mice.
INTRODUCTION
Chagas disease, a neglected parasitic infection, is caused
by the protozoan Trypanosoma cruzi and affects more than
10 million people, mainly in Latin America. Recently, as a
consequence of migratory events, it has been disseminated
to North America and Europe, becoming a serious health
problem in non-endemic regions.1 Benznidazole (BNZ) is one
of the two available drugs prescribed to treat the circulating
forms of the parasite in the acute phase of the infection, but
its efficacy to treat the chronic stage of the disease is still
controversial.2,3 The treatment of Chagas disease should
start immediately after positive diagnosis (acute phase). In
this case, after 60 days of treatment, up to 80% of the
patients can expect its remission.4 However, chemotherapy
with BNZ presents some drawbacks including the dosage
regimen, long treatments, and often appearance of several
side effects such as allergic dermatitis, peripheral neuropa-
thy, and anorexia. BNZ exhibits low water solubility, which
may produce low and/or variable bioavailability after oral
administration. As a consequence, the search of novel BNZ
delivery systems that could be effective for Chagas disease is
still a major priority to control this neglected infection.5
Nanotechnology is a convenient tool to improve the aque-
ous solubility and further bioavailability of hydrophobic
drugs. Even though nanotechnology is widely applied to
develop nanomedicines for several pathologies, including
cancer, cardiovascular and neurodegenerative disorders, lit-
tle is known about nanoformulations for the treatment of
Chagas disease.6,7 Thus, the aim of this study was to evalu-
ate the effectiveness of BNZ nanoparticles (BNZ-nps) on
trypomastigotes forms and on intracellular infection in mam-
malian cells and primary cardiac myocyte cells as compared
with raw BNZ (R-BNZ). Its effectiveness was also evaluated
on acute T. cruzi Nicaragua (TcN) mice infection.8,9
MATERIALS AND METHODS
Materials. BNZ (lot 9978 A; Laboratorios Elea, Buenos
Aires, Argentina) was provided by Instituto Nacional de
Parasitología, ANLIS Malbrán, Ministerio de Salud de la
Nación, (Buenos Aires, Argentina). Lutrol® F-68 (P188)
was donated by BASF SE (Ludwigshafen, Germany). The
following compounds were used in this study: MTT reagent
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
purchased from Sigma Aldrich (Buchs SG, Switzerland);
fetal bovine serum (FBS), Hanks’ balanced salt solution
(HBSS), and Dulbecco’s modified Eagle’s medium (DMEM)
purchased from Gibco (Rockville, MD); horse serum pur-
chased from Internegocios SA (Córdoba, Argentina); kidney
epithelial cells of the African green monkey, Vero cells,
obtained from ABAC (Pergamino, Argentina). All the other
reagents and chemicals used for analytical purpose were of
chromatography grade.
Preparation of BNZ-nps. BNZ-nps were prepared by a
solvent diffusion method. BNZ (200 mg) was dissolved in
ethanol (10 mL). The solution was injected (1 mL/minute)
into water (20 mL) containing P188 (300 mg) under stirring
(1,000 rpm/60 minutes). The resulting solution was stirred
(500 rpm) for 18 hours at room temperature to allow solvent
evaporation. Nanoparticles were then recovered by centrifu-
gation for 20 minutes (15,000 rpm), washed twice with dis-
tilled water, and frozen overnight at −20°C and freeze-dried
(48 hours).
Particle size and Zeta potential measurement. The parti-
cle size of BNZ-nps was determined by photon correlation
spectroscopy using an SZ-100 Horiba equipment (HORIBA
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Instruments Inc., Irvine, CA). The samples were prepared
by 10-fold dilution of 1 mL of the nanoparticles with dis-
tilled water. Zeta potential was determined by the electro-
phoretic mobility of nanoparticles at 25°C, using an SZ-100
Horiba equipment. These determinations were carried out
in triplicate.
Cell toxicity assay. The viability of the kidney epithelial cells
of the African green monkey (Vero) cells was determined by
reduction of yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide to a blue crystalline formazan
product (MTT assay).10
Cells (1 × 105) were seeded in a 96-well plate and were
incubated over night at 37°C with increasing concentrations
of BNZ-nps (10, 25, and 50 μg/mL). Next, MTT was added,
and, to dissolve it, a solution of dimethylformamide and
sodium dodecyl sulfate was added after 2–4 hours. Color
developed was measured at 540 nm in a microplate reader
(model 3550; Bio-Rad, Philadelphia, PA). Each experiment
was done in triplicate.
Hemolytic assay. A 4% suspension of fresh defibrinated
human blood was prepared in a sterile 5% glucose solution
and treated with BNZ-nps (100, 50, 25, and 10 μg/mL) for
24 hours at 37°C.11 After centrifugation, the supernatant
absorbance was determined at 540 nm to assess percent
hemolysis. R-BNZ was used as the hemolytic reference drug
and Triton X-100 (Sigma Aldrich, St. Louis, MO) was used
as the positive control.
Antitrypanosomal activity. Trypomastigotes were obtained
from Vero cell culture. The assay was performed in a sterile
96-well microplate with 50,000 trypomastigotes per well. The
cultures were then incubated at 37°C for 24 hours under a
5% CO2 atmosphere with 90 μL of fresh DMEM medium
supplemented with 20% FBS and 10% of mice blood, and
with 10 μL of each dilution of the R-BNZ and BNZ-nps to
obtain the desire concentration (5–100 μg/mL). The drug
concentration at which 50% of the parasites were lysed
(LC50) was calculated by counting the cells according to
the Brener method.12 In addition, to detect any potential
antitrypanosomal activity of the excipient, this study was
performed using P188 alone. The assay was performed in
duplicate for each of the three different experiments.
Preparation of ventricular myocytes. Ventricular myocytes
were isolated from 5-day-old mice.13 Heart fragments were
dissociated with HBSS with 0.02% trypsin at 37°C for four
cycles of 15 minutes each. The cells were resuspended in
DMEM with 10% FBS and 10% horse serum and transferred
to 12-mm coverslips contained in 24-well culture plates. These
cultures were kept in a 5% CO2 incubator at 37°C to allow
the cells to adhere firmly to the coverslips.
Amastigote growth inhibition assay. Mice cardiac myocytes
(CMs) and Vero cells were incubated in 24-well tissue-
culture plates on 12-mm coverslips as described in the above
section “Preparation of ventricular myocytes.” After 48 hours,
cultured cells were infected with TcN trypomastigotes (para-
sites:cell ratio 10:1) and incubated for 3 hours at 37°C in a 5%
CO2 atmosphere. After CM and Vero cells were washed to
remove the non-internalized parasites, they were incubated
with 10, 25, and 50 μg/mL of BNZ-nps for 24 and 48 hours,
respectively. The coverslips were removed, rinsed with PBS,
fixed in methanol, and stained with Giemsa. In each experi-
ment, a total of 300 cells were evaluated for each treatment in
randomly selected fields. The percentage of growth inhibi-
tion was calculated as ([experimental infected cells − control
infected cells]/[control infected cells]) × 100.14
Animal model. Eight groups, each consisting of 10
1-month-old female C3H/HeN mice, were inoculated intra-
peritoneally with 1,000 culture-derived trypomastigotes of the
TcN isolate. Infected mice were divided into the following
groups: 1) infected mice without treatment, 2) mice treated
with R-BNZ with daily doses of 50 mg/kg body weight for
15 days (2–17 days post infection [dpi]) (R-BNZ), 3) mice
treated with BNZ-nps for 15 days with daily doses of 50 mg/
kg/day (BNZ-nps 50-15), 4) mice treated with BNZ-nps for
30 days with daily doses of 50 mg/kg/day (BNZ-nps 50-30),
5) mice treated with BNZ-nps for 15 days with daily doses of
25 mg/kg/day (BNZ-nps 25-15), 6) mice treated with BNZ-
nps for 30 days with daily doses of 25 mg/kg/day (BNZ-nps
25-30), 7) mice treated with BNZ-nps for 15 days with daily
doses of 10 mg/kg/day (BNZ-nps 10-15), 8) mice treated with
BNZ-nps for 30 days with daily doses of 10 mg/kg/day
(BNZ-nps 10-30), and 9) mice without infection treated with
BNZ nanoparticles for 30 days with daily doses of 50 mg/kg/
day, as reference formulation (BNZ-nps 50 F). R-BNZ and
BNZ-nps were dispersed in olive oil and administered to
mice through oral gavage. Mortality was recorded every day.
All procedures involving experimental protocols in animals
were conducted in accordance with ethical legislation and
regulatory entities established in Argentina and were approved
by the Bioethics Committee of the National Institute of Parasi-
tology “Dr. Mario Fatala Chaben” (registered RENIS N°:
000028), and met the international recommendations for the
use of laboratory animals (World Medical Association in the
Declaration of Helsinki).
Statistical methods. The statistical significant data (P <
0.05) were analyzed by the Student’s t test and analysis of
variance test of the LC50 of trypomastigotes and percent-
age of amastigotes inhibition. To assess differences between
survival curves, a log-rank test of Kaplan–Meier was per-
formed. All tests were performed using GraphPad software
(La Jolla, CA) (Prism 5.0).
RESULTS AND DISCUSSION
BNZ-nps were prepared by using the nanoprecipitation
technique with P188 as a stabilizer. This technique was cho-
sen because of its simplicity, as compared with the emulsifi-
cation process. Thus, complex purification of oily residues
was avoided during the BNZ-np production. BNZ is a hydro-
phobic molecule highly soluble in ethanol, a solvent miscible
with water. Once the drug is dissolved in such solvent and
poured dropwise into the aqueous solution containing P188,
it becomes nontransparent showing the generation of BNZ-
nps.15 Its characterization indicated a mean particle size of
63.3 ± 2.82 nm, a zeta potential of −18.30 ± 1.0, and a size
distribution (polydispersity index) of 3.35 ± 0.1. It is known
that the development of novel nanocarriers is a promising
approach to improve the efficacy of chemotherapeutic
agents. Therefore, taking into account the clinical impor-
tance of BNZ, both biocompatibility and toxicity issues need
to be evaluated. Cell viability studies were performed in rela-
tion to the BNZ-nps toxicity issues by means of the MTT
assay (Table 1). No significant differences were observed
between the optical densities of cells treated with BNZ-nps
(10, 25, and 50 μg/mL) and R-BNZ (50 μg/mL) and the
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optical densities of untreated cells. In addition, no morpho-
logical change or destabilization of the cell membrane was
visible by optical microscopy, indicating that such BNZ-nps
would present desirable properties in terms of cell viability.16
In addition, because of its potential importance in clinical
research, in vitro hemolytic assay was performed to evaluate
whether BNZ-nps might damage red blood cells.17 The opti-
cal density values of treated cells with BNZ-nps and R-BNZ
were similar to the optical density values of the control
untreated blood cells (Table 2), while the positive control,
Triton X-100 (10%), produced a complete lysis of erythro-
cytes. It is worth mentioning that nanoparticles could be con-
sidered safe drug delivery systems to be used as trypanocides,
since no detectable destabilization of the membranes of red
blood cells was observed, as occurs with other nanoparticles
evaluated as carriers for cancer therapy.18
Next, an assay involving nonproliferative trypomastigotes
of TcN was carried out. As observed in Figure 1A, R-BNZ
decreased the survival rate of the infective and nonproliferative
trypomastigote stage with a LC50 of 49 μg/mL. In contrast, as
seen in Figure 1B, a LC50 of 36 μg/mL was obtained in the case
of the BNZ-nps, indicating the suitability of BNZ-nps to treat
both the acute and chronic phase infections. It is worth men-
tioning that P188 did not produce any lytic effect on the
nonproliferative trypomastigotes of TcN (data not shown).
Controls without treatment represent 100% of trypomastigotes.
The lower concentration of R-BNZ reduced the number of
parasites to 80% with respect to untreated controls while
BNZ-nps reduced the parasites to 60% with the same drug
concentration. It is known that the range of parasite susceptibil-
ity to BNZ depends on the strain prevailing in different geo-
graphical areas, and that T. cruzi discrete typing unit (DTU) I,
frequent in endemic areas of northern South America, is gener-
ally resistant to BNZ while isolates of T. cruzi DTU II were
partially resistant to BNZ.19 Previously, it was observed that
TcN epimastigotes DTU I were more resistant to BNZ than
CL Brener epimastigotes DTU VI.8 In this regard, although
there are limits to determine the efficacy of BNZ, its affinity
for cardiac tissue and resistance to BNZ makes it interesting to
study these BNZ-nps in the isolated TcN.
Furthermore, considering that TcN also invades cardiac
cells, the effects of BNZ-nps in infected primary cardiac
myocyte cultures were also studied and compared with infected
Vero cells.8 As shown in Figure 2, treatments with BNZ-nps
25, 50 μg/mL and R-BNZ 50 μg/mL exhibited no significant
differences in the percentage of amastigote growth inhibi-
tion on Vero and cardiac myocyte cells. It is worth mention-
ing that with half the dose of BNZ-nps, the same inhibitory
effect on the growth of amastigotes is achieved. This result
may suggest that BNZ-nps improve the absorption of BNZ
and, therefore, its inhibitory activity against these infected
cell lines.20,21 In contrast, a lower inhibitory activity against
the infected cells in both cell cultures was observed when
the assay was performed using 10 μg/mL of BNZ-nps. How-
ever, taking into account the reported adverse effects of
BNZ on infected patients, these results are remarkably
important in terms of a potential reduction of the BNZ dose
up to 25 μg/mL without losing its efficacy. Moreover, the
inhibitory effects of the formulation observed on the infected
cells may confirm the ability of such nanoparticles to cross
FIGURE 1. Effects of raw benznidazole (R-BNZ) and BNZ nano-
particles (BNZ-nps) on Vero-culture-derived trypomastigotes. After
a 24-hour treatment, antitrypanosomal activity was evaluated as
the drug concentration at which 50% of the parasites were lysed
(LC50). Curves represent log of drug concentration (A) R-BNZ
and (B) BNZ-nps in relation to trypomastigotes percentage by




OD mean Standard deviation
Vero cells 0.765 0.104
R-BNZ (50 μg/mL) 0.782 0.098
BNZ-nps (50 μg/mL) 0.672 0.026
BNZ-nps (25 μg/mL) 0.695 0.009
BNZ-nps (10 μg/mL) 0.717 0.015
BNZ-nps = benznidazole nanoparticles; OD = optical density; R-BNZ = raw benznidazole.
The OD was determined spectrophotometrically at a wavelength of 578 nm. The OD of Vero
cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay
showed no significant differences after the addition of BNZ-nps or R-BNZ. Data were col-
lected from three independent experiments in duplicate.
TABLE 2
Hemolytic assay
OD mean Standard deviation
Control blood 0.466 0.092
R-BNZ (50 μg/mL) 0.659 0.35
BNZ-nps (100 μg/mL) 0.592 0.328
BNZ-nps (50 μg/mL) 0.384 0.028
BNZ-nps (25 μg/mL) 0.413 0.013
BNZ-nps (10 μg/mL) 0.454 0.03
Triton X-100 (10%) 2.617 0.039
BNZ-nps = benznidazole nanoparticles; OD = optical density; R-BNZ = raw
benznidazole. The OD was determined spectrophotometrically at a measuring wave-
length of 540 nm. The OD of blood showed no significant differences before and after
addition of BNZ-nps. R-BNZ was used as the hemolytic reference drug and Triton X-100
(10%) was used as the positive control. Data were collected from three independent experi-
ments in duplicate.
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FIGURE 2. Percentage of inhibition of Trypanosoma cruzi Nicaragua infected Vero cells and cardiac myocytes primary culture, exposed to
benznidazole nanoparticles (BNZ-nps; 10, 25, and 50 μg/mL) and raw BNZ (R-BNZ; 50 μg/mL). In analysis of variance statistical test, no signifi-
cant differences were observed between BNZ-nps (25 μg/mL), BNZ-nps (50 μg/mL), and R-BNZ (50 μg/mL) treatments. In Student’s t test, no
significant differences were observed between the responses of both cell lines.
FIGURE 3. Effects of benznidazole nanoparticles (BNZ-nps) on treatment of infected mice. Survival curve during the acute phase in C3H/
HeN mice infected with 1,000 trypomastigotes of Trypanosoma cruzi Nicaragua and treated with (A) 30 oral doses and (B) 15 oral doses of
BNZ-nps. To assess differences between survival curves, a log-rank test of Kaplan–Meier was performed, which showed significant differences
between treated and untreated infected mice (P < 0.0001).
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the coronary vasculature to inhibit the intracellular growth of
T. cruzi amastigotes.
To ascertain whether BNZ-nps could be used as a novel
treatment of Chagas disease, an assay in the acute phase
of TcN-infected mice was performed. It is also known that
parasitemia in non-treated C3H/HeN mice inoculated with
1,000 trypomastigotes of TcN, peaks at 30–35 dpi and
decreases by 45–50 dpi, resulting only in a 15% survival rate.9
To determine whether differences in infection outcome would
be correlated with different doses of BNZ-nps, a treatment
over 30 consecutive days in infected mice was carried out. As
shown in Figure 3A, the infected mice treated with 50, 25,
and 10 mg/kg/day BNZ-nps for 30 days, survived, at least,
50 days. In addition, the antiparasitic effect of BNZ-nps was
also evaluated over 15 consecutive days of treatment in
infected mice. As observed in Figure 3B, the infected mice
treated with BNZ-nps (50 and 25 mg/kg/day) survived, at
least, 50 days, while the infected mice group treated with
BNZ-nps (10 mg/kg/day) exhibited a survival rate of 70%
after 38 days and till the end of the experiment, confirming
that BNZ formulated as nanoparticles has an in vivo anti-
parasitic effect in dose-dependent manner. In addition, it was
found that both uninfected untreated and uninfected mice
treated with BNZ-nps 50 mg/kg/day had the same weight,
appearance, and behavior confirming the suitability of such
BNZ-nps in suppressing parasitemia and preventing death of
infected TcN mice.
CONCLUSIONS
In summary, for the first time it was shown that nano-
particles of BNZ exhibited a remarkable effect on T. cruzi
amastigote growth inhibition in primary cardiac myocytes. It
was also confirmed that all mice survived acute infection
with 15 doses of 25 or 50 mg/kg/day BNZ-nps during the
assay. These findings led to the conclusion that the BNZ-nps
treatment is a very convenient approach, in different doses
and schedules, to successfully treat Chagas disease in an exper-
imental model of acute T. cruzi infection.
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